CAPR CAPRICOR THERAPEUTICS, INC. Insider Trading

EVP & General Counsel Karen Krasney sells 24,100 CAPR shares at $30.38 for $732.2K; retains 30.5K shares plus 31,261 option shares.

Karen Krasney, EVP and General Counsel, sold 24,100 shares at $30.38 on 2026-06-25, reducing her direct holdings from 54.6K to 30.5K shares (-44.1% of pre-transaction holdings). This is the third open-market sale of CAPR stock by this insider; her prior CAPR sale on 2026-05-01 showed a -5.5% 30-day return, and her 2026-03-31 sale posted a -21.0% 90-day return. The stock currently trades at $23.80, down -41.0% from the 52-week high of $40.37, and has declined -20.6% over the past 30 days. The company remains unprofitable with annual revenue growth of -100.0%, though the insider retains 31,261 shares through stock options plus 30.5K direct shares post-transaction.

CFO Anthony Bergmann sells 24,100 CAPR shares at $30.38; stock down 41.0% from 52-week high, now $23.80

Anthony Bergmann, Chief Financial Officer, sold 24,100 shares of CAPRICOR THERAPEUTICS at $30.38 on 2026-06-25, reducing his non-derivative holdings from 35,323 shares to 11,223 shares. The sale occurred as CAPR trades at $23.80, down 41.0% from its 52-week high of $40.37, and the stock has declined 20.6% over the prior 30 days and 21.7% over the prior 90 days. Fundamentals remain challenging: the company reported quarterly revenue of $2,261,642.00 with net income of $-33,941,345.00, annual revenue growth of -100.0%, and the company remains unprofitable. Notably, Bergmann retains 91,980 shares in derivative securities (stock options), so his overall economic position in CAPR is not fully liquidated despite the substantial reduction in non-derivative shares.

EVP General Counsel sells ~45% of holdings while simultaneously purchasing shares; net exit amid stock recovery from lows.

Krasney Karen, the company's EVP and General Counsel, executed a paired transaction—buying and selling shares on the same day—that reveals a nuanced insider posture. She purchased a meaningful stake while simultaneously liquidating roughly half her total holdings, suggesting neither bullish conviction nor bearish panic, but rather portfolio rebalancing or tax-motivated trading. What's notable is the timing: the stock has recovered significantly from its lows and is trading below its year-to-date highs, yet this C-suite officer is trimming exposure rather than adding. Against the company's challenging fundamentals—operating at a substantial net loss with no current annual revenue—this selective exit from a senior executive raises a yellow flag about near-term confidence. The transaction itself is material enough to trigger SEC thresholds, but the paired buy-sell structure muddles the interpretive signal that a straightforward sale would convey.

CFO Bergmann executes same-day option exercise and full sale, harvesting gains while company burns cash with no revenue.

CFO Anthony Bergmann exercised options and immediately sold the entire position on the same day, converting an acquisition valued at roughly $80,000 into proceeds of approximately $793,000. This is Bergmann's second open-market sale at Capricor in six months, following a prior exit in late March where the stock subsequently rose—indicating poor timing on his previous exit. The current sale appears similarly timed: the stock is trading well below its 52-week high and has declined sharply over the past month, yet Bergmann's last sell did not precede that weakness. More concerning is the company's financial position: Capricor has zero annual revenue, a substantial net loss, and is burning cash while the stock remains above its 52-week low. The lack of any offsetting insider buying activity—despite the CFO's repeated selling—and the company's deteriorating fundamentals suggest Bergmann is reducing exposure rather than showing confidence in a near-term turnaround.

CFO Bergmann sells 25,000 shares of CAPR at $30.13; post-transaction holdings decline to 8,223 shares from 33,223 via 10b5-1 plan

Bergmann Anthony, Chief Financial Officer of Capricor Therapeutics, executed a scheduled sale of 25,000 shares at $30.13 under a pre-arranged 10b5-1 trading plan on 2026-03-31, reducing his holdings by 75.2% from 33,223 shares to 8,223 shares post-transaction. As a 10b5-1 plan, this sale was pre-established and executed automatically rather than reflecting a discretionary decision tied to current market conditions or company outlook. The magnitude of the reduction—eliminating three-quarters of his equity stake—reflects the plan's scheduled parameters, and the low remaining ownership level (8,223 shares) may limit future signaling value from this insider's trading activity.

Director Sabar Karimah Es sells entire 115,000-share position (100.0% of holdings) for $3.5M under 10b5-1 plan

Director Sabar Karimah Es executed 2 separate sales totaling 115,000 shares for $3,515,467.62 across 2026-03-31 and 2026-04-01, liquidating their complete shareholding at a blended average price of $30.57. This represents a 100.0% reduction in the director's position. The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating these sales were scheduled in advance rather than discretionary decisions made in response to current market conditions or company developments. The complete exit of a director's equity stake merits investor attention as a data point about insider equity positioning, though the scheduled nature of the plan precludes timing-based inference.

EVP General Counsel Karen Krasney sold 25,000 shares of CAPR at $30.12 (10b5-1 plan) for $752.9K; holdings fell 45.0%

Krasney sold 25,000 shares at $30.12 for $752.9K, reducing her holdings from 55,547 to 30,547 shares—a 45.0% reduction. This transaction is part of a pre-arranged 10b5-1 trading plan and therefore is scheduled rather than discretionary. Because the sale is governed by a formal plan, it reflects execution of a pre-determined schedule rather than a real-time market judgment. The scale of the reduction—nearly half her prior holdings—represents material portfolio action by a senior legal executive, though the non-discretionary nature limits inference about current company conditions or insider conviction.

Nippon Shinyaku (10% owner) buys 2,798,507 shares of CAPR at $5.36 for $15.0M; position grows to 7,090,351 shares (+65.2%)

Nippon Shinyaku, already a 10% shareholder, committed $14,999,997.52 to increase its stake in Capricor Therapeutics by 65.2%, acquiring 2,798,507 shares at $5.36. The stock has since appreciated to $9.10, up 99.6% over 30 days and 96.5% over 90 days, suggesting the transaction occurred near a recent floor—a critical timing inflection. Set against Capricor's fundamentals (unprofitable with -$11.0M net income, quarterly revenue of $4.0M, but explosive annual growth of +886.8%), this represents a major capital commitment by an existing anchor investor rather than a new entrant. The purchase size and subsequent price trajectory merit investor scrutiny into what triggered this significant further concentration of ownership and whether it signals conviction in a turnaround or precedes material strategic announcements.